Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 1;17(12):5101-5106.
doi: 10.22034/APJCP.2016.17.12.5101.

A New Inflammatory Prognostic Index, Based on C-reactive Protein, the Neutrophil to Lymphocyte Ratio and Serum Albumin is Useful for Predicting Prognosis in Non-Small Cell Lung Cancer Cases

Nigar Dirican  1 , Ahmet Dirican, Ceyda Anar, Sule Atalay, Onder Ozturk, Ahmet Bircan, Ahmet Akkaya, Munire Cakir
Affiliations

A New Inflammatory Prognostic Index, Based on C-reactive Protein, the Neutrophil to Lymphocyte Ratio and Serum Albumin is Useful for Predicting Prognosis in Non-Small Cell Lung Cancer Cases

Nigar Dirican et al. Asian Pac J Cancer Prev. .

Abstract

Purpose: We aimed to establish an inflammatory prognostic index (IPI) in early and advanced non-small cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to analyze its predictive value for NSCLC survival. Materials and Methods: A retrospective review of 685 patients with early and advanced NSCLC diagnosed between 2009 and 2014 was conducted with collection of clinical, and laboratory data. The IPI was calculated as C-reactive protein × NLR (neutrophil/ lymphocyte ratio)/serum albumin. Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors. Results: The optimal cut-off value of IPI for overall survival (OS) stratification was determined to be 15. Totals of 334 (48.8%) and 351 (51.2%) patients were assigned to high and low IPI groups, respectively. Compared with low IPI, high IPI was associated with older age, greater tumor size, high lymph node involvement, distant metastases, advanced stage and poor performance status. Median OS was worse in the high IPI group (low vs high, 8.0 vs 34.0 months; HR, 3.5; p<0.001). Progression free survival values of the patients who had high vs low IPI were determined 6 months (95% CI:5.3-6.6) and 14 months (95% CI:12.1-15.8), respectively (HR; 2.4, P<0.001). On multivariate analysis, stage, performance status, lactate dehydrogenase and IPI were independent prognostic factors for OS. Subgroup analysis showed IPI was generally a significant prognostic factor in all clinical variables. Conclusion: The described IPI may be an inexpensive, easily accessible and independent prognostic index for NSCLC patients, useful for clinical practice.

Keywords: Index; inflammatory; lung cancer; prognosis; survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall Survival Curves Comparing Patients with NSCLC with a High IPI vs Low IPI
Figure 2
Figure 2
Progression-Free Survival Curves Comparing Patients with NSCLC with a High IPI vs Low IPI
Figure 3
Figure 3
Forest Plot for Subgroup Analysis of Overall Survival. Survival is for low IPI vs high IPI. Data are derived from Cox’s analysis without covariates. HR, hazard ratio; CI, confidence interval; KPS, Karnofsky performance status; IPI, inflammatory prognostic index
See this image and copyright information in PMC

References

    1. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618–26. - PubMed
    1. Azab B, Chainani V, Shah N, McGinn JT. Neutrophil–lymphocyte ratio as a predictor of majör adverse cardiac events among diabetic population: A 4-year follow-up study. Angiology. 2013;64:456–5. - PubMed
    1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45. - PubMed
    1. Celikbilek M, Dogan S, Ozbakır O, et al. Neutrophil–lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal. 2013;27:72–6. - PMC - PubMed
    1. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7. - PMC - PubMed